Regentis Biomaterials Develops New Manufacturing Process For GelrinC, Off-The-Shelf Hydrogel Synchronized Erosion And Resorbable Implant For Treatment Of Painful Injuries To Focal Articular Knee Cartilage

Regentis Biomaterials has developed a new patented manufacturing process for its GelrinC hydrogel implant, designed for treating focal articular knee cartilage injuries. This innovative, solvent-free process significantly increases production yield by over four times per batch. The company is preparing for a commercial launch of GelrinC in Europe later this year, with the patent pending in the U.S.